Abstract

Neisseria meningitidis is a major global pathogen causing invasive disease with a mortality of 5–10%. Most disease in developed countries is caused by serogroup B infection, against which there is no universal vaccine. Opacity-associated adhesin (Opa) proteins are major meningococcal outer membrane proteins, which have shown recent promise as a potential novel vaccine. Immunisation of mice with different Opa variants elicited high levels of meningococcal-specific bactericidal antibodies, demonstrating proof in principle for this approach. Opa proteins are critical in meningococcal pathogenesis, mediating bacterial adherence to host cells, and modulating human cellular immunity via interactions with T cells and neutrophils, although there are conflicting data regarding their effects on CD4+ T cells. We constructed Opa-positive and Opa-negative meningococcal strains to allow further evaluation of Opa as a vaccine component. All four opa genes from N. meningitidis strain H44/76 were sequentially disrupted to construct all possible combinations of N. meningitidis strains deficient in one, two, three, or all four opa genes. The transformations demonstrated that homologous recombination of exogenous DNA into the meningococcal chromosome can occur with as little as 80 bp, and that minor sequence differences are permissible. Anti-Opa bactericidal antibody responses following immunisation of mice with recombinant Opa were specific to the Opa variant used in immunisation. No immunomodulatory effects were observed when Opa was contained within meningococcal outer membrane vesicles (OMVs), compared to Opa-negative OMVs. These observations support the incorporation of Opa in meningococcal vaccines.

Highlights

  • Neisseria meningitidis causes up to 500,000 cases of meningitis and septicaemia worldwide annually, with a mortality rate of approximately 10% [1]

  • Opa proteins are a potential novel vaccine candidate for the prevention of meningococcal disease caused by all serogroups, and have the potential to protect against the hyperinvasive isolates which are responsible for most of the disease burden [20,21]

  • Bactericidal antibodies are currently accepted as the correlate of protection against meningococcal disease, and anti-Opa bactericidal antibodies have been demonstrated in patients following infection with N. meningitidis and in recipients of serogroup B outer membrane vesicles (OMVs) vaccines [22,23,24,25,26,27,28,29]

Read more

Summary

Introduction

Neisseria meningitidis causes up to 500,000 cases of meningitis and septicaemia worldwide annually, with a mortality rate of approximately 10% [1]. Most cases of disease are caused by 5 of the 13 meningococcal serogroups: A, B, C, Y and W135. Opa proteins are a potential novel vaccine candidate for the prevention of meningococcal disease caused by all serogroups, and have the potential to protect against the hyperinvasive isolates which are responsible for most of the disease burden [20,21]. Bactericidal antibodies are currently accepted as the correlate of protection against meningococcal disease, and anti-Opa bactericidal antibodies have been demonstrated in patients following infection with N. meningitidis and in recipients of serogroup B OMV vaccines [22,23,24,25,26,27,28,29]. The potential expression of multiple Opa proteins from any given isolate has made it difficult to study the immunoprotective or immunomodulatory effects of specific Opa proteins expressed on the bacterial surface

Methods
Results
Conclusion

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.